Connor Clark & Lunn Investment Management Ltd. Takes $3.74 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Connor Clark & Lunn Investment Management Ltd. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,839 shares of the medical research company's stock, valued at approximately $3,739,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.05% of Charles River Laboratories International at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Rothschild Investment LLC grew its holdings in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after purchasing an additional 144 shares during the period. HM Payson & Co. bought a new position in shares of Charles River Laboratories International in the first quarter worth about $31,000. Optiver Holding B.V. bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $37,000. GeoWealth Management LLC increased its position in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in Charles River Laboratories International by 83.7% during the first quarter. Parallel Advisors LLC now owns 474 shares of the medical research company's stock valued at $71,000 after purchasing an additional 216 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CRL shares. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Wall Street Zen lowered Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. raised their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Barclays lifted their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a report on Thursday, August 7th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $175.69.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded up $0.86 during mid-day trading on Friday, hitting $156.66. 1,038,291 shares of the stock were exchanged, compared to its average volume of 1,079,568. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The stock's fifty day simple moving average is $156.87 and its two-hundred day simple moving average is $148.86. The stock has a market capitalization of $7.71 billion, a price-to-earnings ratio of -117.79, a P/E/G ratio of 5.00 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.80 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 400 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the sale, the executive vice president directly owned 24,916 shares of the company's stock, valued at approximately $3,738,396.64. This represents a 1.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).